Former Bridgecorp managing director Rob Petricevic, already serving a six-and-a-half year jail sentence, has pleaded guilty to four fraud charges.
The Serious Fraud Office (SFO) brought charges against the Petricevic relating to the fraudulent acquisition and financing of a luxury launch, the ‘Medici’, purchased using $3.5 million of Bridgecorp money.
A fraudulent transaction took place to finance, hide or disguise the purchase of Medici from the Bridgecorp Board, the Trustee, and investors, the SFO alleged.
Petricevic also made substantial payments to a Panmure spray tanner, Janita Wright who was to be a witness at the trial.
He admitted four charges at the Auckland District Court this afternoon. Other charges were withdrawn.
Petricevic will now serve an additional four months in prison, on top of his current jail term.
The SFO's prosecution of Petricevic's co-accused Rob Roest, also behind bars, will still go ahead.
Both men are serving six-and-a-half-year jail sentences imposed after a separate trial, brought by the Financial Markets Authority, in which they were found guilty of misleading investors who lost $459 million when Bridgecorp collapsed in 2007.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- New lawyers not doing 'much better' than job at McDonald's – report surprises
- MARKET CLOSE: NZ shares gain as market bounce continues; Kathmandu, Fletcher rise
- Auditors warn of Seadragon's going concern ability as firm breaches covenant
- New hotel to go ahead in Auckland as govt looks to boost tourism investment
- Marlborough-based wine company lists on the NXT despite OIO hiccup
Most listened to
- Marlborough Wine Estates CEO Catherine Ma explains why the Chinese-owned company listed on the NXT
- National list MP Chris Bishop says Phil Twyford's accusation the government has made housing a 'race issue' is hypocritical
- Bond prices have fallen while oil prices have risen - Jason Walls explains why on Walls' Street
- NBR technology editor Chris Keall on hitting 4000 member subscribers
- In his Editor's Insight Nevil Gibson on the future of health information technology and medical devices industry